Fig. 1From: MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603T-ReCS identified two major mRNA clusters (a) and one major cluster of three miRNAs (b) as predictive of progression-free survival (PFS), represented at heatmaps. Patients are ordered from shortest to longest progression-free survival (c)Back to article page